MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination

    J. Ellmen, J. Tuunainen, A. Holopainen, T. Sarapohja, M. Scheinin (Turku, Finland)

    Objective: To evaluate the plasma pharmacokinetics (PK) of orally administered modified release (MR) levodopa in combination with the aromatic L-amino acid decarboxylase inhibitor carbidopa and…
  • 2016 International Congress

    Creatine for patients with Parkinson’s disease: A meta-analysis

    A. Attia, H. Ahmed, M. Morsi, K. Awad, M. Elnenny, E. Ghanem, A. Negida (Cairo, Egypt)

    Objective: The aim of this systematic review and meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the efficacy of creatine for…
  • 2016 International Congress

    Effects of nilotinib on safety in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

    F. Pagan, E. Valadez, Y. Torres-Yaghi, R. Falconer, R. Mills, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)

    Objective: Nilotinib is FDA-approved for the treatment of chronic myeloid leukemia (CML) at 800mg oral dose twice daily. We examined the effects of lower doses…
  • 2016 International Congress

    Nilotinib improves motor skills, cognition and autonomic function in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

    F. Pagan, E. Valadez, Y. Torres-Yaghi, A. Keys, R. Falconer, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)

    Objective: Nilotinib, a tyrosine kinase inhibitor (TKI) was examined with the aim of showing its effect on safety comparing a lower dose of 150mg (N=6)…
  • 2016 International Congress

    Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

    C. Moussa, E. Valadez, Y. Torres-Yaghi, A. Keys, R. Falconer, S. Rogers, B. Wilmarth, M. Hebron, F. Pagan (Washington, DC, USA)

    Objective: The objective was to determine whether Nilotinib crosses the blood brain barrier (BBB). Background: Parkinson's disease (PD) involves death of dopamine producing neurons in…
  • 2016 International Congress

    Efficacy and feasibility study of the Medido eletronic medication dispenser in Parkinson’s disease: A multicentre randomized controlled trial

    K. Hannink, L. ter Brake, A. Wertenbroek, K. Movig, J. van der Palen, L. Dorresteijn (Enschede, Netherlands)

    Objective: The aim of this randomized controlled study was to assess the effect of the electronic medication dispenser, Medido, on physical limitations in PD. Background:…
  • 2016 International Congress

    Day case initiation of subcutaneous apomorphine in people with Parkinson’s disease: A retrospective analysis from a UK teaching hospital

    K. Nalamada, J. Cosgrove, P. Duggan-Carter, S. Jamieson, J. Alty (Leeds, United Kingdom)

    Objective: To evaluate a cohort of people with Parkinson's disease (PD) who were initiated on subcutaneous apomorphine injections or continuous subcutaneous apomorphine infusions (CSAI) on…
  • 2016 International Congress

    Effects of combined repetitive transcranial magnetic stimulation and treadmill training on gait performance in Parkinson’s disease

    C.L. Chung, M.K.Y. Mak (Hong Kong, Hong Kong)

    Objective: To evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) with treadmill training on walking performance and corticomotor excitability in people with Parkinson's disease…
  • 2016 International Congress

    Peri-operative dopaminergic replacement protocol with rotigotine in Parkinson’s disease patients

    L. Abraira del Fresno, L. Ispierto, A.M. Crespo, T. Canento, D. Vilas, M. Gonzalez, F. Sala, L. Morató, J. Sánchez-Ojanguren, R. Álvarez (Barcelona, Spain)

    Objective: To evaluate the accomplishment of a peri-operative dopaminergic replacement protocol established in our centre from 2011 to 2014, and analyse the main factors associated…
  • 2016 International Congress

    Group climate in the voice therapy of patients with Parkinson’s disease

    G.L.A. Diaféria, P.B. Takaki, G. Madazio, C. Pacheco, M.S. Behlau (São Paulo, Brazil)

    Objective: To examine the impact of coaching and group dynamics activities in the voice, speech and communication of Parkinson's disease (PD) patients, as well as…
  • « Previous Page
  • 1
  • …
  • 1713
  • 1714
  • 1715
  • 1716
  • 1717
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28953 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley